

Title (en)  
USE OF BETA-ADRENOCEPTOR AGONISTS IN COMBINATION WITH NMDA ANTAGONISTS FOR THE TREATMENT OF  
NEURODEGENERATIVE DISEASES

Title (de)  
VERWENDUNG VON BETA-ADRENOCEPTOR-AGONISTEN IN KOMBINATION MIT NMDA-ANTAGONISTEN ZUR BEHANDLUNG VON  
NEURODEGENERATIVEN ERKRANKUNGEN

Title (fr)  
UTILISATION D'AGONISTES DE L'ADRENOCEPTEUR BETA EN COMBINAISON AVEC DES ANTAGONISTES DU NMDA POUR TRAITER DES  
AFFECTIONS NEURODEGENERATIVES

Publication  
**EP 1420772 A2 20040526 (DE)**

Application  
**EP 02797607 A 20020822**

Priority  
• DE 10142175 A 20010829  
• DE 10142176 A 20010829  
• DE 10142178 A 20010829  
• DE 10149611 A 20011009  
• EP 0209369 W 20020822

Abstract (en)  
[origin: WO03020257A2] The invention relates to the use of beta -adrenoceptor agonists for restoring and/or maintaining the function of partially or fully damaged/degenerated cells of the central nervous system and/or other nerve cells. Using beta 2-adrenoceptor agonists enables astrocytes to be activated and endogenous neuroprotection processes to be stimulated, whereby the damage or destruction of nerve cells can be reduced and even prevented in some cases.

IPC 1-7  
**A61K 31/135; A61K 31/167; A61K 31/522; A61P 25/16; A61P 25/28; A61K 31/136**

IPC 8 full level  
**A61K 45/00** (2006.01); **A61K 31/135** (2006.01); **A61K 31/136** (2006.01); **A61K 31/137** (2006.01); **A61K 31/167** (2006.01);  
**A61K 31/522** (2006.01); **A61P 1/16** (2006.01); **A61P 3/00** (2006.01); **A61P 3/10** (2006.01); **A61P 9/12** (2006.01); **A61P 13/12** (2006.01);  
**A61P 17/02** (2006.01); **A61P 21/04** (2006.01); **A61P 25/00** (2006.01); **A61P 25/14** (2006.01); **A61P 25/16** (2006.01); **A61P 25/28** (2006.01);  
**A61P 25/32** (2006.01); **A61P 27/02** (2006.01); **A61P 27/16** (2006.01); **A61P 39/02** (2006.01); **A61P 43/00** (2006.01); **C12N 5/079** (2010.01);  
**C12N 5/0793** (2010.01)

CPC (source: EP)  
**A61K 31/135** (2013.01); **A61K 31/136** (2013.01); **A61K 31/167** (2013.01); **A61K 31/522** (2013.01); **A61P 1/16** (2017.12); **A61P 3/00** (2017.12);  
**A61P 3/10** (2017.12); **A61P 9/12** (2017.12); **A61P 13/12** (2017.12); **A61P 17/02** (2017.12); **A61P 21/04** (2017.12); **A61P 25/00** (2017.12);  
**A61P 25/14** (2017.12); **A61P 25/16** (2017.12); **A61P 25/28** (2017.12); **A61P 25/32** (2017.12); **A61P 27/02** (2017.12); **A61P 27/16** (2017.12);  
**A61P 39/02** (2017.12); **A61P 43/00** (2017.12); **C12N 5/0619** (2013.01); **C12N 5/0622** (2013.01); **C12N 2501/999** (2013.01)

Citation (search report)  
See references of WO 03020257A2

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

DOCDB simple family (publication)  
**WO 03020257 A2 20030313; WO 03020257 A3 20040108**; AU 2002333510 A1 20030318; EP 1420772 A2 20040526;  
JP 2005505548 A 20050224; PL 373490 A1 20050905

DOCDB simple family (application)  
**EP 0209369 W 20020822**; AU 2002333510 A 20020822; EP 02797607 A 20020822; JP 2003524566 A 20020822; PL 37349002 A 20020822